Mark Whitlock
Overview
Explore the profile of Mark Whitlock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robinson P, Toussi S, Aggarwal S, Bergman A, Zhu T, Hackman F, et al.
Open Forum Infect Dis
. 2023 Aug;
10(8):ofad355.
PMID: 37559753
Background: An urgent need remains for antiviral therapies to treat patients hospitalized with COVID-19. PF-07304814-the prodrug (lufotrelvir) and its active moiety (PF-00835231)-is a potent inhibitor of the SARS-CoV-2 3CL protease....
2.
Mi M, Whitlock M, Shi X, Farrell L, Bhambhani V, Quadir J, et al.
Am J Clin Nutr
. 2023 Feb;
117(3):529-539.
PMID: 36811472
Background: Elevated BCAA levels are strongly associated with diabetes, but how diabetes affects BCAA, branched-chain ketoacids (BCKAs), and the broader metabolome after a meal is not well known. Objective: To...
3.
Saxena A, Lyle S, Khavandi K, Qiu R, Whitlock M, Esler W, et al.
Diabetes Obes Metab
. 2022 Dec;
25(4):992-1001.
PMID: 36515213
Aim: To assess the safety, tolerability and pharmacodynamics (PD) of the ketohexokinase inhibitor PF-06835919 in participants with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). Materials And Methods:...
4.
Gurrell R, Whitlock M, Wei H, Shen Z, Ogden A
Clin Pharmacol Drug Dev
. 2021 Jan;
10(7):756-764.
PMID: 33465277
Multiple-dose pharmacokinetics (PK) and safety were investigated in this phase 1 study of PF-06372865, a positive allosteric modulator of α2/3/5 subunit-containing γ-aminobutyric acid A receptors (NCT03351751). In 2 cohorts (7-8...
5.
Wanigasekera V, Wartolowska K, Huggins J, Duff E, Vennart W, Whitlock M, et al.
Br J Anaesth
. 2019 Apr;
123(2):e166-e171.
PMID: 30979518
No abstract available.
6.
van Amerongen G, Siebenga P, Gurrell R, Dua P, Whitlock M, Gorman D, et al.
Br J Anaesth
. 2019 Mar;
123(2):e194-e203.
PMID: 30915991
Background: This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel α2/α3/α5 gamma-aminobutyric acid A (GABA) subunit selective partial positive allosteric modulator (PAM),...
7.
Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds D, DiVentura B, et al.
Neurology
. 2019 Mar;
92(15):e1786-e1795.
PMID: 30877186
Objective: The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABA receptors with minimal activity at α1-containing...
8.
Simen A, Whitlock M, Qiu R, Miceli J, Zumpano L, Du Metz M, et al.
J Clin Psychopharmacol
. 2018 Dec;
39(1):20-27.
PMID: 30531477
Background: Generalized anxiety disorder (GAD) is a common psychiatric disorder, but many patients experience only partial relief of symptoms with existing therapies. Benzodiazepines are effective in many cases but are...
9.
Gurrell R, Dua P, Feng G, Sudworth M, Whitlock M, Reynolds D, et al.
Pain
. 2018 May;
159(9):1742-1751.
PMID: 29787472
The effect of PF-06372865, a subtype-selective positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor, on chronic low back pain was investigated in a randomised, placebo- and active-controlled...
10.
Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder
Targum S, Murphy C, Khan J, Zumpano L, Whitlock M, Simen A, et al.
Innov Clin Neurosci
. 2018 May;
15(3-4):37-42.
PMID: 29721364
: The assessment of patients with generalized anxiety disorder (GAD) to deteremine whether a medication intervention is necessary is not always clear and might benefit from a second opinion. However,...